Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results
Travere Therapeutics Provides Corporate Update and 2023 Outlook
Liquidia Enters Into a Revenue Interest Financing Agreement With HealthCare Royalty for Up to $100 Million
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases
BioArctic's partner Eisai submits supplemental Biologics License Application to FDA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer's disease
Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company's Vision to Transform Patient Outcomes in Rare Diseases
Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2023
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease
ADDF STATEMENT ON FDA ACCELERATED APPROVAL OF LECANEMAB (LEQEMBI)
 13   14   15   16   17     18    19   20   21   22   23 
 <<   <   >   >>